<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00117039</url>
  </required_header>
  <id_info>
    <org_study_id>20030206</org_study_id>
    <nct_id>NCT00117039</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness of Aranesp® for Cancer Patients With Anemia</brief_title>
  <official_title>SYNCHRONICITY: A Study to Evaluate the Effectiveness of Aranesp® at 300 Mcg Q3W on Clinical Outcomes in Cancer Patients With Anemia Due to Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the effectiveness of Aranesp® administered at 300 mcg
      every 3 weeks (q3w) in achieving therapeutic objectives of anemia treatment (achieving and
      maintaining hemoglobin levels consistent with the National Comprehensive Cancer Network
      (NCCN) guidelines).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>April 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin maintenance</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in measures of work productivity and anemia treatment convenience</measure>
  </secondary_outcome>
  <enrollment>1500</enrollment>
  <condition>Anemia</condition>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aranesp®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subjects with non-myeloid malignancy - Anemia (Hgb less than 11.0
        g/dL) due to cancer chemotherapy - Receiving chemotherapy and expected to receive at least
        8 additional weeks of chemotherapy - Adequate renal function - Adequate liver function
        Exclusion Criteria: - Subjects with acute myelogenous leukemia (AML), chronic myelogenous
        leukemia (CML), or myelodysplastic syndromes (MDS) - Unstable cardiac disease - Active
        bleeding - Active systemic or chronic infection - Severe active chronic inflammatory
        disease - Other hematologic disorder associated with anemia - Uncontrolled hypertension -
        Known iron or nutritional deficiency - Known positive test for human immunodeficiency virus
        (HIV) infection - History of pure red cell aplasia - History of positive antibody response
        to any erythropoietic agent - Erythropoietin therapy within 4 weeks before screening - RBC
        transfusions within 2 weeks prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.aranesp.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Boccia R, Lillie T, Tomita D, Balducci L. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist. 2007 May;12(5):584-93.</citation>
    <PMID>17522247</PMID>
  </results_reference>
  <results_reference>
    <citation>Boccia R, Malik IA, Raja V, Kahanic S, Liu R, Lillie T, Tomita D, Clowney B, Silberstein P. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia. Oncologist. 2006 Apr;11(4):409-17.</citation>
    <PMID>16614237</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2005</study_first_posted>
  <last_update_submitted>October 14, 2008</last_update_submitted>
  <last_update_submitted_qc>October 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>fatigue</keyword>
  <keyword>Aranesp®</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

